South Korea Oral Anti-Diabetic Drug Market Report by Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides), and Region 2024-2032

South Korea Oral Anti-Diabetic Drug Market Report by Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A17653
Buy Now

Market Overview:

South Korea oral anti-diabetic drug market size is projected to exhibit a growth rate (CAGR) of 3.20% during 2024-2032. The growing prevalence of diabetes among the masses due to the adoption of unhealthy diets, increasing integration of smart devices with drug delivery mechanisms, and rising influence of patient advocacy groups represent some of the key factors driving the market.

Report Attribute
 Key Statistics                   
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Growth Rate (2024-2032) 3.20%


Oral anti-diabetic drug, also known as oral hypoglycemic agent, is a class of pharmaceutical compound specifically designed to lower blood sugar levels among individuals with diabetes. It comprises biguanides like metformin, which reduces the production of glucose and enhances insulin sensitivity. It also consists of sulfonylureas, such as glibenclamide and glipizide, which increases insulin production. It often enhances insulin production by the pancreas and improves the sensitivity of cells to insulin, allowing better glucose uptake. It also slows down the absorption of glucose in the gut and inhibits the production of glucose by the liver. It is often used in combination with each other or with insulin to achieve better glycemic control. It is more convenient than insulin injections, which can improve patient adherence to treatment plans. It also helps control blood sugar levels, reducing the risk of complications, such as heart disease, kidney disease, nerve damage, and vision problems. It allows healthcare providers to tailor treatments as per the age, severity of diabetes, and existing health conditions of an individual.

South Korea Oral Anti-Diabetic Drug Market Trends:

At present, the increasing prevalence of diabetes among the masses due to the consumption of unhealthy diets and the adoption of sedentary lifestyle habits represents one of the crucial factors impelling the growth of the market in South Korea. Besides this, the growing awareness about the importance of early diagnosis and treatment, coupled with improvements in healthcare infrastructure and accessibility, is expanding the patient pool seeking pharmacological interventions. In addition, the rising research and development (R&D) activities are facilitating the production of various novel drugs that are not only effective in managing blood sugar levels, but also offer additional benefits, such as weight loss and cardiovascular risk reduction. Apart from this, the integration of smart devices with drug delivery mechanisms enables real-time monitoring and personalized dosing adjustments, thereby contributing to better disease management. Furthermore, combination therapies that combine multiple drug classes in a single medication are prescribed by doctors to address the multifaceted nature of diabetes are simplifying treatment regimens for patients and improving medication adherence. Moreover, the growing influence of patient advocacy groups and the increasing role of social media in healthcare is bolstering the market growth in the country. Furthermore, patients are becoming more involved in their treatment decisions and are demanding drugs that not only effectively manage diabetes but also align with their lifestyle and preferences. This trend is pushing pharmaceutical companies operating in the country to focus on patient feedback and develop medications that cater to these evolving needs.

South Korea Oral Anti-Diabetic Drug Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on drugs.

Drugs Insights:

  • Biguanides
    • Metformin
  • Alpha-Glucosidase Inhibitors
  • Dopamine D2 Receptor Agonist
    • Bromocriptin
  • SGLT-2 Inhibitors
    • Invokana (Canagliflozin)
    • Jardiance (Empagliflozin)
    • Farxiga/Forxiga (Dapagliflozin)
    • Suglat (Ipragliflozin)
  • DPP-4 Inhibitors
    • Onglyza (Saxagliptin)
    • Tradjenta (Linagliptin)
    • Vipidia/Nesina (Alogliptin)
    • Galvus (Vildagliptin)
  • Sulfonylureas
  • Meglitinides
     

The report has provided a detailed breakup and analysis of the market based on the drugs. This includes biguanides (metformin), alpha-glucosidase inhibitors, dopamine D2 receptor agonist (bromocriptin), SGLT-2 inhibitors (invokana (canagliflozin), jardiance (empagliflozin), farxiga/forxiga (dapagliflozin), and suglat (ipragliflozin)), DPP-4 inhibitors (onglyza (saxagliptin), tradjenta (linagliptin), vipidia/nesina (alogliptin), and galvus (vildagliptin)), sulfonylureas, and meglitinides.

Regional Insights:

  • Seoul Capital Area
  • Yeongnam (Southeastern Region)
  • Honam (Southwestern Region)
  • Hoseo (Central Region)
  • Others
     

The report has also provided a comprehensive analysis of all the major regional markets, which include Seoul Capital Area, Yeongnam (Southeastern Region), Honam (Southwestern Region), Hoseo (Central Region), and Others.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

South Korea Oral Anti-Diabetic Drug Market Report Coverage:

Report Features Details
Base Year of the Analysis 2023
 Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Million
Scope of the Report Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment: 
  • Drugs
  • Region  
Drugs Covered
  • Biguanides: Metformin
  • Alpha-Glucosidase Inhibitors
  • Dopamine D2 Receptor Agonist: Bromocriptin
  • SGLT-2 Inhibitors: Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), Suglat (Ipragliflozin)
  • DPP-4 Inhibitors: Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia/Nesina (Alogliptin), Galvus (Vildagliptin)
  • Sulfonylureas
  • Meglitinides
Regions Covered Seoul Capital Area, Yeongnam (Southeastern Region), Honam (Southwestern Region), Hoseo (Central Region), Others
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3699
Five User License: US$ 4699
Corporate License: US$ 5699
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report:

  • How has the South Korea oral anti-diabetic drug market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the South Korea oral anti-diabetic drug market?
  • What is the breakup of the South Korea oral anti-diabetic drug market on the basis of drugs?
  • What are the various stages in the value chain of the South Korea oral anti-diabetic drug market? 
  • What are the key driving factors and challenges in the South Korea oral anti-diabetic drug?
  • What is the structure of the South Korea oral anti-diabetic drug market and who are the key players?
  • What is the degree of competition in the South Korea oral anti-diabetic drug market? 

Key Benefits for Stakeholders:

  • IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the South Korea oral anti-diabetic drug market from 2018-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the South Korea oral anti-diabetic drug market.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the South Korea oral anti-diabetic drug industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
South Korea Oral Anti-Diabetic Drug Market Report by Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More